Travere Therapeutics to Present at Upcoming Investor Conferences
Travere Therapeutics, Inc. (NASDAQ: TVTX) announced its participation in two significant upcoming conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Travere Therapeutics, Inc. (NASDAQ: TVTX) announced its participation in two significant upcoming conferences. The SVB Securities Global Biopharma Conference is scheduled for February 15, 2023, at 3:00 p.m. ET, followed by the Barclays Global Healthcare Conference on March 15, 2023, at 11:15 a.m. ET. Live webcasts of each presentation will be available on Travere's Investor page, with replays accessible for up to 30 days post-event. Travere is dedicated to developing therapies for patients facing rare diseases, focusing on their urgent treatment needs and striving to offer hope through innovative solutions.
Details
News Market Reaction – TVTX
The recorded move for TVTX in the trading session of this news was +1.33%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will participate in the following upcoming conferences:
SVB Securities Global Biopharma Conference
Wednesday, February 15, 2023, at 3:00 p.m. ET
Barclays Global Healthcare Conference
Wednesday, March 15, 2023, at 11:15 a.m. ET
Live webcasts of the presentations will be accessible on the Investor page of Travere’s website at ir.travere.com/events-presentations. Replays will be available for up to 30 days following each event.
About Travere Therapeutics
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com
Contact:
Naomi Eichenbaum
Vice President, Investor Relations
IR@travere.com
888-969-7879
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.